Diagnostic value of fetal hemoglobin Bart’s for evaluation of fetal α-thalassemia syndromes: application to prenatal characterization of fetal anemia caused by undiagnosed α-hemoglobinopathy

Kritsada Singha1,2, Supawadee Yamsri1, Attawut Chaibunruang1, Hataichanok Srivorakun1, Kanokwan Sanchaisuriya1, Goonnapa Fucharoen1 and Supan Fucharoen1*

Abstract

Background: To evaluate whether the quantification of fetal hemoglobin (Hb) Bart’s is useful for differentiation of α-thalassemia syndromes in the fetus and to characterize the fetal anemia associated with fetal α-hemoglobinopathy.

Methods: A total of 332 fetal blood specimens collected by cordocentesis were analyzed using capillary electrophoresis and the amount of Hb Bart’s was recorded. The result was evaluated against thalassemia genotypes determined based on Hb and DNA analyses. Prenatal Hb and DNA characterization of the fetal anemia observed in two families was done.

Results: Among 332 fetuses investigated, Hb and DNA analyses identified 152 fetuses with normal genotypes. The remaining 180 fetuses carried α-thalassemia with several genotypes. Variable amounts of Hb Bart’s were identified in all fetuses with α-thalassemia, which could be used for simple differentiation of fetal α-thalassemia genotypes. These included α+– and α0-thalassemia traits, homozygous α+–thalassemia and Hb Constant Spring (CS), Hb H disease, Hb H-CS and Hb H-Quong Sze diseases, homozygous α0-thalassemia causing the Hb Bart’s hydrops fetalis and a remain uncharacterized α-thalassemia defect. The previously undescribed interactions of Hb Queens Park and Hb Amsterdam A1 with Hb E were detected in two fetuses with Hb Bart’s of 0.5%. The Hb Queens Park-AEBart’s disease was also noted in one pregnant woman. Prenatal analysis of the fetuses with severe fetal anemia and cardiomegaly with Hb Bart’s of 9.0% and 13.6% revealed unexpectedly the homozygous Hb CS and a compound heterozygosity of Hb CS/Hb Pakse’ with Hb E heterozygote, respectively.

Conclusions: The usefulness of detecting and differentiation of fetal α-thalassemia syndromes by quantifying of Hb Bart’s was demonstrated. Apart from the fatal condition of Hb Bart’s hydrops fetalis associated with homozygous α0-thalassemia, homozygous Hb CS and a compound Hb CS/Hb Pakse’ could result in severe fetal anemia and fetal
Introduction

α-Thalassemia is one of the most common inherited hemoglobin (Hb) disorders. In northeast Thailand, the prevalence of α-thalassemia is around 30%, consisting of both α⁰-thalassemia (5–6%) and α⁺-thalassemia (24–25%). α⁰-Thalassemia caused by a deletion of two α-globin genes (αα/αα) is the most severe form which in the homozygous state can lead to a fatal condition known as Hb Bart’s hydrops fetalis. Most of the α⁺-thalassemia caused by the deletion of one α-globin gene (αα/αα) is generally mild [1, 2]. Interaction of these α-thalassemia leads to the Hb H disease, and interaction of Hb H disease with Hb E leads to complex syndromes of AEBart’s, EFBart’s, and EEBart’s diseases, with thalassemia intermedia phenotypes, commonly encountered in the region [3–6]. However, the interaction of α⁰-thalassemia with non-deletional α⁺-thalassemia and some forms of homozygous α⁰-thalassemia caused by point mutations may result in more severe clinical phenotype and unstable Hbs, requiring appropriate management, treatment, and genetic counseling [7–9]. Therefore, identification of these α-thalassemia defects is essential. Unfortunately, in Thailand and other Southeast Asian countries, the prevention and control program of thalassemia only targets at three severe thalassemia diseases, including homozygous α⁰-thalassemia, β-thalassemia major, and β-thalassemia/Hb E disease. The program aims to offer carrier screening and identify carriers of α⁰-thalassemia, β-thalassemia, and Hb E [10, 11]. Prenatal diagnosis is then offered to a couple at risk of having a fetus with the three thalassemia diseases. Other thalassemia genotypes are not included. Fetal α-thalassemia genotypes are defined by DNA analysis [12].

At our routine service for thalassemia, when prenatal diagnosis is performed on fetal blood specimen, we also carry out Hb analysis using capillary electrophoresis in addition to DNA analysis. We evaluate in this study if this Hb analysis which is relatively simpler compared to DNA analysis, is helpful in a routine prenatal diagnosis and differentiation of fetal α-thalassemia syndromes in areas with high prevalence and diverse heterogeneity of thalassemia and hemoglobinopathies.

Materials and methods

Subjects and hematological analyses

Ethical approval of the study protocol was obtained from the Institutional Review Board of Khon Kaen University, Khon Kaen, Thailand (HE 622173). Retrospective data at the routine thalassemia diagnostic service at the Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Thailand, were collected from a total of 332 fetal blood specimens subjected to prenatal diagnosis of α-thalassemia. The specimen was collected using the method of cordocentesis, and maternal cell contamination was monitored in each fetal specimen using the Hb F cell staining [12]. Complete blood count was performed using a standard blood cell counter. Hb analysis was performed using the capillary electrophoresis (CapillaryS 2; Sebia, Lisses, France).

Routine DNA analysis

Common α-thalassemia found in Thailand (α⁰-SEA, α⁰-THAI, -α⁴², Hb Constant Spring (HBA2:c.427T>C) and Hb Pakse’ (HBA2:c.429A>T), α-globin gene triplication (ααα), Hb variants, and Hb E were identified routinely using PCR-related techniques as described elsewhere [12–15]. Hb Quong Sze mutation (HBA2: c.377T>C) on an α2-globin gene was identified by PCR–RFLP assay using MspI restriction digestion (5′-C▼GG-3′) as described [16]. Uncharacterized samples were further examined by direct DNA sequencing. Thalassemia genotypes were defined based on the results of these DNA analyses.

Identification of α⁰-Hb Amsterdam A1 and α⁰-Hb Queens Park mutations

To provide a method for rapid identification of the α⁰-Hb Amsterdam A1, and α⁰-Hb Queens Park mutations found in this study, the PCR–RFLP assay using BtsCI restriction enzyme was developed. This method has been described for detection of the α⁰-Ivs1-117(G>A) mutation (HBA1:c.96-1G>A) located in the vicinity of the two variants on α1-globin gene [6, 17]. Selective amplification of α1-globin specific fragment (975 bp) was performed by PCR using primers C1 (5′-GCCTCTTTTGCAACCATTCT AA-3′) and B (5′-AATGCACTGACCTCCCCACAT-3′). The PCR product was digested to completion with BtsCI complications, prenatal diagnosis is highly recommended. The simple Hb Bart’s quantification of fetal blood should prove helpful in this matter.

Keywords: Hemoglobin Bart’s, α-Thalassemia syndrome, Hemoglobin Constant Spring, Prenatal diagnosis, Fetal anemia
restriction enzyme (5′-GGATGNN^{-3′}) (New England Biolabs, Beverly, MA, USA). A normal control fragment is digested into the 457 bp, and 518 bp fragments, whereas the 975 bp remain undigested fragment indicates the α^{+} Amsterdam A1, and α^{+} Queens Park mutations.

**Prenatal characterization of fetal anemia and cardiomegaly**

Prenatal characterization was performed on two unrelated families. In Family 1 (Fig. 1), the father was diagnosed on Hb analysis as Hb E heterozygote, whereas his pregnant wife was a carrier of Hb CS. Based on the protocol used in a prevention and control program of thalassemia in Thailand, they had no risk of having fetus with severe thalassemia disease. However, in the second trimester of pregnancy, the fetus developed fetal anemia due to an unknown cause. Fetal blood was taken by cordocentesis at a gestational age of 27 weeks and transferred to us for thalassemia investigation. In Family 2 (Fig. 2), fetal blood was taken at a gestational age of 34 weeks because of fetal anemia and fetal cardiomegaly. The mother was diagnosed based on Hb analysis as homozygous Hb E and her husband was a normal subject with MCV 85.9 fl. As for family 1, they had no risk of having fetus with severe thalassemia. The fetal blood was sent to us for thalassemia investigation.
Results
Among 332 fetuses investigated for α-thalassemia, DNA analysis revealed 152 (45.8%) fetuses with normal α-globin genes. Various α-thalassemia genotypes at different frequencies were found in the remaining 180 (54.2%) fetuses (Table 1). As shown in the table, in addition to normal fetuses, as many as 12 different α-thalassemia genotypes were encountered. The data indicated a diverse heterogeneity of α-thalassemia in our population. Among 180 fetuses with α-thalassemia, 57 (31.7%) were α-thalassemic fetuses with Hb Bart’s hydrops fetalis caused by homozygous α0-thalassemia (−/−). As this fatal thalassemic disease is one of the targets for prevention and control program and is associated with serious maternal complications, genetic counselling was given, and therapeutic abortion was offered in all cases. Other α-thalassemia genotypes encountered included α0-thalassemia trait (n=44), α+-thalassemia trait (n=26), homozygous Hb CS or compound heterozygous Hb CS/Hb Pakse’ (n=14), Hb CS trait (n=12), Hb H disease (n=7), Hb H-CS or Hb H-Pakse’ disease (n=6), double heterozygous for α+-thalassemia/Hb CS (n=5), homozygous α+-thalassemia (n=4), Hb H-Queens Park Sze (n=1) and four unknown

Table 1  Fetal Hb Bart’s identified in each corresponding α-globin genotype

| Item   | Type                  | Number | α-Genotype | Hb Bart’s (%) |
|--------|-----------------------|--------|------------|---------------|
| 1      | Non α-thalassemia     | 152    | αα/αα      | 0             |
| 2      | Hb Bart’s Hydrops fetalis | 57   | −/−        | 81.5 ± 3.6 (74.7–89.9) |
| 3      | α0-thalassemia trait  | 44     | α0/αα      | 4.8 ± 1.2 (1.9–8.0)  |
| 4      | α+-thalassemia trait  | 26     | α-/αα      | 0.7 ± 0.4 (0–1.5)  |
| 5      | Homozygous Hb CS and Hb CS/Hb PS | 14  | αCS/αCS (11), αCS/αCS (3) | 11.2 ± 2.6 (7.4–16.7) |
| 6      | Hb CS trait           | 12     | αCS/αα     | 1.3 ± 0.8 (0.4–2.9) |
| 7      | Hb H disease          | 7      | −/−α       | 192 ± 1.5 (16.9–22.1) |
| 8      | Hb H-CS and Hb H-Pakse’ diseases | 6   | −/αCS (5), −/αCS (1) | 263 ± 1.8 (23.4–28.2) |
| 9      | α+-thalassemia/Hb CS  | 5      | αCS/α-α   | 7.3 ± 2.2 (4.8–9.9) |
| 10     | Homozygous α+-thalassemia | 4   | αCS/α-α | 4.1 ± 1.5 (2.1–5.8) |
| 11     | Rare α+-thalassemia trait | 2   | αCS/αα | 0.5 |
| 12     | Hb H-QZ disease       | 1      | −/αQZα    | 33.7 |
| 13     | Unknown               | 2      | na         | 0.7, 1.4 |
| Total  |                       | 332    |            |               |

Values are presented as mean ± SD (range)
na not available
CS = Hb Constant Spring, PS = Hb Pakse’, QP = Hb Queens Park, Ams = Hb Amsterdam A1, QZ = Hb Quong Sze

Fig. A Pedigree analysis of a family in which the fetus was a double heterozygote for Hb Queens Park/Hb E. The father was a carrier of α+-thalassemia (SEA deletion) and the mother was a patient with Hb H-Queens Park disease with Hb E heterozygote (the Hb Queens Park-AEHb’s). Hematological parameters of all members are listed. B Pedigree analysis of a family in which the fetus was double heterozygote for Hb Amsterdam A1/Hb E. No blood specimen of the father was available. Hematological parameters of the mother and the fetus are listed.
Further DNA sequencing of these four fetuses identified a double heterozygosity for Hb E and Hb Queens Park (α1 CD 32 ATG (Met) > AAG (Lys)) in one fetus and a double heterozygosity for Hb E and Hb Amsterdam A1 (α1 CD 32 ATG (Met) > ATA (Ile)) (data not shown), previously undescribed in the fetus (Fig. 3A, B). The two α-hemoglobinopathies could be confirmed using PCR–RFLP assay using BtsCI restriction enzyme as shown in Fig. 4. The α-thalassemia genotypes in two fetuses remained uncharacterized. As shown in Table 1, while Hb analysis of the fetal blood specimens detected no Hb Bart’s in the normal fetuses, variable amounts of Hb Bart’s were identified in the α-thalassemic fetuses. The amounts of Hb Bart’s corresponded with the severity of α-globin gene defects, i.e., highest in the Hb Bart’s hydrops fetalis (81.5±3.6%) followed by Hb H disease, homozygous Hb CS, double αThalassemia/Hb CS, α+thalassemia trait, and α−thalassemia trait, as shown in Fig. 5. Interestingly, as high as 33.7% Hb Bart’s was detected in the fetus with Hb H-Quong Sze disease, who had severe anemia and developed hydrops fetalis. DNA analysis identified heterozygosity for α0-thalassemia in the father and Hb Queens Park in the mother, as shown in Fig. 6. Prenatal characterization of the cases with fetal anemia and fetal cardiomegaly was done in two families (Figs. 1, 2). In family 1, the father was preliminarily diagnosed with Hb E heterozygote with 27.1% Hb E while the mother was a heterozygous Hb CS. Since the fetus developed fetal anemia and cardiomegaly of an unknown etiology, fetal blood was taken by cordocentesis at gestational age of 27 weeks for thalassemia investigation. Figure 1 listed hematological parameters of the fetus with Hb 5.1 g/dL and numerous nucleated RBC (750/100 WBC). Hb analysis identified Hb CS (3.1%), Hb F-CS (1.2%), Hb Bart’s (9.0%) and Hb H (0.3%) in addition to the Hb A. DNA analysis revealed unexpectedly that the fetus was a homozygous Hb CS and identified the Hb CS gene in the father and the mother. Therefore, the father was in fact, a double heterozygote for Hb E/Hb CS, although Hb CS was not detected on Hb A analysis. In family 2, according to the family history, the mother was a homozygous Hb E, and the father demonstrated a normal MCV value (85.9 fL). Unfortunately, their blood specimens were not available for further testing. As shown in Fig. 2, analysis of fetal blood taken at a gestational age of 34 weeks identified Hb 9.8 g/dL and nucleated RBC (225/100 WBC). Hb analysis identified Hb E-CS (0.4%), Hb F-CS (1.2%), Hb Bart’s (13.6%) and Hb H (0.3%) in addition to the Hb
DNA analysis of α-globin gene identified that the fetus was a compound heterozygous for Hb CS/Hb Pakse’ with Hb E heterozygote.

Discussion

Identifying α-thalassemia, especially α0-thalassemia is an essential step in a prevention and control program of severe thalassemia in Southeast Asia and China. Couples who both carry α0-thalassemia have a 25% risk of having offspring with Hb Bart’s hydrops fetalis caused by a homozygous α0-thalassemia, an emerging health care issue.
problem in many populations [17]. The disease is one of the targets of the prevention and control program of thalassemia in the region. In addition, the interaction of α-thalassemia and α-thalassemia leads to the Hb H disease, a thalassemia intermedia commonly encountered in the region. Some forms of Hb H disease, especially the non-deletional form, can lead to a severe phenotype and Hb H hydrops fetalis [18]. Accurate diagnosis of these α-thalassemia syndromes requires DNA analysis which could not be applied in the rural areas in the regions.

In the initial recognition of subjects with α-thalassemia, assay with anti-Hb Bart’s monoclonal antibody can help of adult subjects using immunochromatographic strip qualitative detection of Hb Bart’s in peripheral blood could be minimal [3–5]. It has been demonstrated that the α-thalassemia syndromes requires DNA analysis which could not be applied in the rural areas in the regions.

The α-globin gene defects causing α-thalassemia result in excess of γ-globin chain (in the fetus) and β-globin chain (in adult), leading to the polymerization to form γ tetramer (Hb Bart’s) and β tetramer (Hb H). The appearance of Hb Bart’s and Hb H in peripheral blood are therefore good markers for α-thalassemia syndromes. In an adult, it is not difficult to detect Hb H in peripheral blood using either Hb H inclusion test or Hb-HPLC and capillary electrophoresis analysis [18, 19]. The Hb H inclusion test is relatively labor intensive and lacks sensitivity, especially in detecting double heterozygotes for α-thalassemia with Hb E and β-thalassemia because the β tetramer could be minimal [3–5]. It has been demonstrated that qualitative detection of Hb Bart’s in peripheral blood of adult subjects using immunochromatographic strip assay with anti-Hb Bart’s monoclonal antibody can help in the initial recognition of subjects with α-thalassemia although the test is not specific [20]. In the fetus and newborns, however, identification of Hb Bart’s is valid for detecting homozygous α-thalassemia causing Hb Bart’s hydrops fetalis. In this most severe form of thalassemia, about 75% or more of Hb Bart’s, without Hb F and Hb A is usually observed [21–24]. This has been confirmed in Table 1, in which fetuses with Hb Bart’s hydrops fetalis (n = 57) had 81.5 ± 3.6% Hb Bart’s as measured by capillary electrophoresis. We found that an appearance of 75% of more Hb Bart’s in combination with no Hb F and Hb A is a definite diagnosis for Hb Bart’s hydrops fetalis with 100% accuracy, and α-globin genotyping by DNA analysis is not necessary.

The usefulness of quantification of fetal Hb Bart’s in prenatal diagnosis of severe α-thalassemia disease has been described. Unfortunately, in a previous preliminary study of Srivorakun et al. [21], fetal blood analysis was performed only on four α-thalassemia genotypes with relatively small numbers of samples i.e., homozygous α-thalassemia (n = 4), Hb H disease (n = 3), α-thalassemia carrier (n = 11) and α-thalassemia carrier (n = 3). Non deletional α-thalassemia and many other α-thalassemia genotypes were not examined. Accordingly, the exact reference level of Hb Bart’s of each α-thalassemia genotype could not be ascertained. In the current study, as many as 12 α-thalassemia genotypes including both common and rare, and deletional and non-deletional types with higher numbers of subjects were studied, as listed in Table 1. Therefore, the expression level of Hb Bart’s for each α-thalassemia genotype could be reliably determined.

Interestingly, as shown in Table 1 and Fig. 5, the amount of Hb Bart’s varied with the severity of the α-thalassemia syndromes. Thanks to the Hb-capillary electrophoresis, which can accurately report the amount of Hb Bart’s. The levels of Hb Bart’s were 33.7% in Hb H-Queens Park disease, 26.3 ± 1.8% in Hb H-CS and Hb H-Pakse’ diseases and 19.2 ± 1.5% in Hb H disease. Although the fetus with Hb H-Queens Park disease is reported here for the first time in Thailand, it has been shown in a Chinese patient that the disease was associated with severe anemia and Hb H hydrops fetalis [25]. Further reduction of Hb Bart’s to 11.2 ± 2.6% was noted in homozygous Hb CS and compound Hb CS/Hb Pakse’ disease (n = 14, Table 1), indicating a more excess γ-globin chain as compared to the α-thalassemia trait (4.8 ± 1.2%) and homozygous α-thalassemia (4.1 ± 1.5%). In this Hb CS disease, many fetuses have been associated with hydropic change suggesting fetal anemia, requiring intrauterine transfusion for effective management [8, 9, 26]. Early diagnosis of the case is therefore essential. Examples are illustrated in Fig. 1 (homozygous Hb CS) and Fig. 2 (compound heterozygote for Hb CS/Hb Pakse’ with Hb E). The latter has been reported herein for the first time in the fetus. Both fetuses were associated with fetal anemia and cardiomegaly. It is noteworthy that patient 1 had lower Hb and Hct values than patient 2. This is likely due to the difference in gestational ages at which the fetal blood samples were analyzed. These were 27 and 34 weeks for patients 1 and 2, respectively. It has been shown that hematological parameters varied with gestational age. An increase in gestational age is associated with increased Hb and Hct and decreased MCV, MCH, and MCHC values [27–29]. In addition, a co-inheritance of the Hb E, which is a β-globin chain variant, in patient 2 may help in the improvement of the hematological phenotype of the patient. Hb analysis of the fetal blood samples identified Hb Bart’s 9.0% and 13.6%, respectively. As in the Hb CS trait, the level of Hb Bart’s was 1.3 ± 0.8% (Table 1), the average level of Hb Bart’s at 11.2 ± 2.6% is a useful diagnostic marker for a homozygous Hb CS and a compound Hb CS/Hb Pakse’ diseases. Prenatal diagnosis of the diseases is recommended so that earlier and appropriate management can be given.

In our study, two rare α-thalassemia variants were encountered for the first time in the fetuses i.e. the Hb Queens Park (HBA1c.98T>A) [a32(B13)Met→Lys] (Fig. 3A) and Hb Amsterdam A1 (HBA1c.99G>A) [a32(B13)Met→Ile] (Fig. 3B). The latter was found for the first time in association with Hb E heterozygote.
The levels of Hb Bart’s at 0.5% in both fetuses confirmed that these two α-thalassemia variants are mild forms of α-thalassemia. Hb Queens Park has been reported originally in a patient of Western Australia with a mild thalassemia phenotype [30]. Association of Hb Queens Park with α-thalassemia (SEA deletion) led to the non-deletional Hb H disease in a Thai boy with a mild clinical phenotype comparable to that of the common deletional Hb H disease [31]. Herein described is for the first time Hb Queens Park was identified in association with Hb E in the fetus and with α-thalassemia (SEA deletion) and Hb E trait, leading to the Hb Queens Park AEBart’s disease in the mother who demonstrated a thalassemia intermedia phenotype (Fig. 3A). Hb Amsterdam A1 is a rare hyperunstable α chain variant due to perturbation of globin-heme and αβ1 subunit interactions [32]. Identifying a Thai fetus with double heterozygote for Hb E/Hb Amsterdam A1 is the second report of this rare α-thalassemia variant ever documented in the literature. Since no abnormal Hb band corresponding to the Hb Amsterdam A1 was visible on alkaline electrophoresis, high performance liquid chromatography (HPLC), and capillary electrophoresis, screening for this α-thalassemia variant should be done by PCR–RFLP assay using BtsC1 restriction enzyme as shown in Fig. 4. This method could identify all the three α-thalassemia mutations found in the region namely Hb Queens Park, Hb Amsterdam A1, and IVS1-117 (G-A), recently described in a Laos patient [6].

In conclusion, our results demonstrated that analysis of fetal Hb using capillary electrophoresis could be an effective alternative to DNA characterization of fetal α-thalassemia syndromes. In fact, any method of Hb analysis should be applicable, provided the quantitative identification of Hb Bart’s is accurately reported. Our results in Table 1 and the previous study using anti-Hb Bart’s monoclonal antibody [20] indicate likely that fetal red blood cells of all α-thalassemia syndromes found in the region contain adequate amounts of Hb Bart’s for accurate quantification. Although, as compared to the chorionic villi sampling and amniocentesis, cordocentesis to obtain fetal blood specimen is not a common practice in prenatal diagnosis, it is still helpful for late pregnancy and for those of at-risk couples whose mutations are not characterized [12]. The fetal blood analysis and quantification of Hb Bart’s using capillary electrophoresis which is simple, rapid, fully automated, and applicable in most routine prenatal diagnosis laboratories should facilitate a prevention and control program for severe thalassemia diseases in the region.

Acknowledgements
We thank Drs. Thawalwong Ratanasiri, Ratana Komwilaikade and Piyamas Saksinwuttho of the Department of Obstetrics and Gynecology, Faculty of Medicine, Khon Kaen University for help in specimen collection.

Authors’ contributions
KS performed the laboratory investigation, analyze the data, and wrote the original manuscript. SY, AC and HS helped in laboratory investigation and clinical data acquisition. Kanokwan S and GF performed data analysis and interpretation. SF is the main investigator, responsible for conception and design of the work, critically reviewing and final approval of the article, research grant acquisition and accountability for all aspects of the work.

Funding
This work was supported by Khon Kaen University, Khon Kaen (to Fucharoen S), and Faculty of Medicine, Mahasarakham University, Mahasarakham (to Singh K), Thailand. SF is a recipient of the Thailand Research Fund (TRF) Research Team Promotion Grant (RTA) of the Thailand Science Research and Innovation (TSRI), Thailand (Contract ID RTA6280005).

Availability of data and materials
Please contact corresponding author for data request.

Declarations

Ethics approval and consent to participate
Ethical approval of the study protocol was obtained from the Institution Review Board (IRB) of Khon Kaen University, Thailand (HE622173).

Consent for publication
Not applicable. No individual person's data and details are utilized in this paper.

Completing interests
The authors declare that they have no completing interests.

Author details
1 Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand. 2 Faculty of Medicine, Mahasarakham University, Mahasarakham, Thailand.

Received: 12 October 2021 Accepted: 30 January 2022
Published online: 10 February 2022

References
1. Fucharoen S, Winichagoon P. Thalassemia in Southeast Asia: problem and strategy for prevention and control. Southeast Asian J Trop Med Pub Health. 1992;23:647–55.
2. Tritipsombut J, Sanchaisuriya K, Phollarp P, et al. Micromapping of thalassemia and hemoglobinopathies in different regions of northeast Thailand and Vientiane. Lao PDR Hemoglobin. 2012;36:47–56.
3. Boonsa S, Sanchaisuriya K, Fucharoen G, Wangnon S, Jetsrisuparb A, Fucharoen S. The diverse molecular basis and hematological features of Hb H and AEBart’s diseases in northeast Thailand. Acta Haematol. 2004;111:149–54.
4. Fucharoen S, Fucharoen G, Sae-ung N, Sanchaisuriya K. Thalassemia intermedia associated with the Hb Constant Spring EE Bart’s disease in pregnancy: a molecular and hematological analysis. Blood Cells Mol Dis. 2007;39:195–8.
5. Chaibunruang A, Karnpean R, Fucharoen G, Fucharoen S. Genetic heterogeneity of hemoglobin AEBart’s disease: a large cohort data from a single referral center in northeast Thailand. Blood Cells Mol Dis. 2014;52:176–80.
6. Singh K, Srivorakun H, Fucharoen G, Fucharoen S. Molecular basis of Hb H and AEBart’s diseases in the Lao People’s Democratic Republic. Int J Lab Hematol. 2020;42:23–7.
7. Kwaifa IK, Lai MI, Noor SM. Non-deletional alpha thalassemia: a review. Orphanet J Rare Dis. 2020;15:166.
8. Charoenkwan P, Sirichotiyakul S, Chanprapaph P, et al. Anemia and hydrops in a fetus with homozygous hemoglobin Constant Spring. J Pediatr Hematol Oncol. 2006;28:827–30.

9. Sinert S, Charoenkwan P, Sirichotiyakul S, et al. Prenatal diagnosis and management of homozygous hemoglobin Constant Spring disease. J Perinatol. 2019;39:927–33.

10. Fucharoen G, Sanchaisuriya K, Sae-ung N, Dangwibul S, Fucharoen S. A simplified screening strategy for thalassemia and haemoglobin E in rural communities in south-east Asia. Bull World Health Organ. 2004;82:364–72.

11. Sanchaisuriya K, Fucharoen S, Fucharoen G, et al. A reliable screening protocol for thalassemia and hemoglobinopathies in pregnancy: an alternative approach to electronic blood cell counting. Am J Clin Pathol. 2005;123:113–8.

12. Yamri S, Sanchaisuriya K, Fucharoen G, Sae-ung N, Ratanasiri T, Fucharoen S. Prevention of severe thalassemia in northeast Thailand: 16 years of experience at a single university center. Prenat Diagn. 2010;30:540–6.

13. Chaibunruang A, Prommetta S, Yamsri S, Fucharoen G, Sae-Ung N, Sanchaisuriya K, Fucharoen S. Molecular and hematological studies in a large cohort of α0-thalassemia in northeast Thailand: data from a single referral center. Blood Cells Mol Dis. 2013;51:89–93.

14. Charoenwijitkul T, Singha K, Fucharoen G, et al. Molecular characteristics of aα-thalassemia (3.7 kb deletion) in Southeast Asia. Molecular subtypes, haplotypic heterogeneity, multiple founder effects and laboratory diagnostics. Clin Biochem. 2019;71:31–7.

15. Srivorakun H, Singha K, Fucharoen G, Sanchaisuriya K, Fucharoen S. A large cohort of hemoglobin variants in Thailand: molecular epidemiological study and diagnostic consideration. PLoS ONE. 2014;9:e108365.

16. Laosombat V, Wiriyasitakul A, Changtrakul Y, Fucharoen S. Rapid detection of an α-thalassemia variant (Hb Quong Sze). Haematologica. 2003;88:ELT27.

17. Chui DH, Wave JS. Hydrops fetalis caused by α-thalassemia: an emerging health care problem. Blood. 1998;91:2213–22.

18. Chui DH. Alpha-thalassemia. Hb H disease and Hb Bart's hydrops fetalis. Ann N Y Acad Sci. 2005;1054:25–32.

19. Fucharoen G, Yooyen K, Chaibunruang A, Fucharoen S. A newly modified hemoglobin H inclusion test as a secondary screening for α-thalassemia in Southeast Asian populations. Acta Haematol. 2014;132:10–4.

20. Prayalaw P, Fucharoen G, Fucharoen S. Routine screening for α-thalassemia using an immunochromatographic strip assay for hemoglobin Bart’s. J Med Screen. 2014;21:120–5.

21. Srivorakun H, Fucharoen G, Sae-ung N, Sanchaisuriya K, Ratanasiri T, Fucharoen S. Analysis of fetal blood using capillary electrophoresis system: a simple method for prenatal diagnosis of severe thalassemia diseases. Eur J Haematol. 2009;83:57–65.

22. Fucharoen S, Winichagoon P, Wisedpanichkij R, et al. Prenatal and postnatal diagnoses of thalassemias and hemoglobinopathies by HPLC. Clin Chem. 1998;44:740–8.

23. Sanguansermsri T, Thanaratanakorn P, Steger HF, et al. Prenatal diagnosis of hemoglobin Bart's hydrops fetalis by HPLC analysis of hemoglobin in fetal blood samples. Southeast Asian J Trop Med Public Health. 2001;32:180–5.

24. Trithipsombat J, Sanchaisuriya K, Fucharoen S, et al. Hemoglobin profiles and hematologic features of thalassemic newborns: application to screening for α-thalassemia 1 and hemoglobin E. Arch Pathol Lab Med. 2006;132:1739–45.

25. Li DZ, Liao C, Li J, Xie XM, Huang YN, Wu QC. Hemoglobin H hydrops fetalis syndrome resulting from the association of the—SEA deletion and the alpha Quong Sze alpha mutation in a Chinese woman. Eur J Haematol. 2005;75:259–61.

26. Komvilaisak P, Komvilaisak R, Jetrisuparb A, et al. Fetal anemia causing hydrops fetalis from an alpha-globin variant: homozygous hemoglobin Constant Spring. J Pediatr Hematol Oncol. 2018;40:405–8.

27. Karnpean R, Fucharoen G, Fucharoen S, Ratanasiri T. Fetal red blood cell parameters in thalassemia and hemoglobinopathies. Fetal Diagn Ther. 2013;34:166–71.

28. Forestier F, Daffos F, Galactéros F, Bardakjian J, Rainaut M, Beuzard Y. Hematological values of 163 normal fetuses between 18 and 30 weeks of gestation. Pediatr Res. 1986;20:342–6.

29. Zhan W, Guo H, Hu S, et al. Comparison of cord blood hematological parameters among normal, α-thalassemia, and β-thalassemia fetuses between 17 and 38 weeks of gestation. Sci Rep. 2021;11:3844.

30. Phylipsen M, Prior JF, Lim E, et al. Two new alpha1-globin gene point mutations: Hb Nedlands (HBA1:c.86C>T) [alpha32(B9)Ala→Val] and Hb Queens Park (HBA1:c.98T>A) [alpha32(B13)Met→Lys]. Hemoglobin. 2010;34:123–6.

31. Sryomora S, Jindadamrongwech S, Butthep P, Chuncharuee S. Nondiagnostic Hb Queens Park [alpha32(B13)Met→Lys]/Hb H (beta4) disease. Hemoglobin. 2012;36:293–8.

32. Brennan SQ, Wang D, Horridge M, Sheen CR, Hb Amsterdam-A1 (α32B13 Met→Ile; HBA1:c.99G>A); a hyperunstable variant due to a new mutation on the α1 gene. Hemoglobin. 2017;41:140–3.